Survival benefit of concurrent chemoradiotherapy for advanced ampulla of Vater cancer

Table 3 Baseline characteristics between the ampulla of Vater cancer patients with and without concurrent chemoradiotherapy

Characteristics	CCRT (n = 11)	Non-CCRT (n = 18)	Total (n = 29)	P value
Sex (%)				0.647
Male	9 (81.8)	12 (66.7)	21 (72.4)
Female	2 (18.2)	6 (33.3)	8 (27.6)
Age, median (IQR)	60 (52; 63)	75.5 (63.3; 79.5)	65 (60; 76)	0.007b
Size, median (IQR)	2.9 (1.9; 3.8)	2.7 (2.2; 3.0)	2.7 (2.1; 3.2)	0.928
T stage (%)				0.200
2	3 (27.3)	2 (11.1)	5 (17.2)
3	7 (63.6)	16 (88.9)	23 (79.3)
4	1 (9.1)	0 (0.0)	1 (3.4)
LN metastasis (%)				1.000
Negative	5 (45.5)	9 (50.0)	14 (48.3)
Positive	6 (54.5)	9 (50.0)	15 (51.7)
LVI (%)				1.000
Negative	7 (63.6)	12 (66.7)	19 (65.5)
Positive	4 (36.4)	6 (33.3)	10 (34.5)
PNI (%)				0.661
Negative	5 (45.5)	11 (61.1)	16 (55.2)
Positive	6 (54.5)	7 (38.9)	13 (44.8)
Differentiation (%)				0.076
Well-to-moderate	4 (36.4)	14 (77.8)	18 (62.1)
Poor	6 (54.5)	3 (16.7)	9 (31.0)
Unknown	1 (9.1)	1 (5.6)	2 (6.9)
Bilirubin	4.6 (1.3; 11.9)	2.8 (0.5; 13.7)	4.1 (0.9; 12.9)	0.515
CEA (%)				1.000
< 5 ng/mL	8 (88.9)	14 (87.5)	22 (88.0)
≥ 5 ng/mL	1 (11.1)	2 (12.5)	3 (12.0)
CA19.9 (%)				0.866
< 39 U/L	3 (30.0)	7 (41.2)	10 (37.0)
≥ 39 U/L	7 (70.0)	10 (58.8)	17 (63.0)
CRP (%)				0.297
< 0.5 mg/dL	1 (11.1)	7 (38.9)	8 (29.6)
≥ 0.5 mg/dL	8 (88.9)	11 (61.1)	19 (70.4)
Albumin (%)				1.000
3.3-5.2 g/dL	10 (90.9)	17 (94.4)	27 (93.1)
< 3.3 or > 5.2 g/dL	1 (9.1)	1 (5.6)	2 (6.9)
PLR, median (IQR)	277.0 (215.1; 291.7)	159.8 (124.1; 237.9)	202.0 (133.9; 287.5)	0.044a
NLR, median (IQR)	4.1 (3.3; 4.5)	2.7 (2.2; 4.7)	3.6 (2.3; 4.6)	0.334
ASA				0.105
I	3 (27.3)	0 (0.0)	3 (10.3)
II	6 (54.5)	11 (61.1)	17 (58.6)
III	2 (18.2)	6 (33.3)	8 (27.6)
IV	0 (0.0)	1 (5.6)	1 (3.4)

^aP < 0.05.

^bP < 0.01.

LN: Lymph node; LVI: Lymphovascular invasion; PNI: Perineural invasion; CCRT: Concurrent chemoradiotherapy; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CRP: C-reactive protein; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; ASA: American Society of Anesthesiologists.